SCHEDULE: Lincoln Alternative Strategies Divests Calidi Biotherapeutics Stake

Lincoln Alternative Strategies LLC reports 0% beneficial ownership in Calidi Biotherapeutics, Inc., indicating a full divestment of its previous stake.

Summary

• Lincoln Alternative Strategies LLC filed an Amendment No. 1 to Schedule 13G regarding its holdings in Calidi Biotherapeutics, Inc.
• The reporting person, Lincoln Alternative Strategies LLC, now beneficially owns 0 shares of Calidi Biotherapeutics' common stock.
• This represents 0% of the class of securities.
• The filing indicates no sole or shared voting or dispositive power over any shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal for Calidi Biotherapeutics, as a significant institutional investor has fully exited its position, which could imply a lack of confidence or a shift in investment priorities.

Negatives

• Lincoln Alternative Strategies LLC has fully divested its beneficial ownership in Calidi Biotherapeutics, Inc., now holding 0% of the common stock.

Industry Context

StockSavvy.ai notes that institutional investor divestments, such as this one by Lincoln Alternative Strategies LLC from Calidi Biotherapeutics, are common occurrences in the dynamic biotech sector. Such movements can reflect shifts in investment strategy, portfolio rebalancing, or a change in outlook on a specific company or sub-sector, though the specific reasons are not disclosed in this filing.

Stakeholder Impact

• Shareholders: Existing shareholders might view the divestment by an institutional investor negatively, potentially leading to downward pressure on the stock price.

Key Dates

Recommendation

Lincoln Alternative Strategies LLC's complete divestment of its stake in Calidi Biotherapeutics, reducing beneficial ownership to 0%, signals a lack of confidence or a strategic exit by a sophisticated institutional investor. This action typically precedes or accompanies a negative outlook on the company's future prospects or valuation, warranting a 'sell' recommendation for investors.

Keywords

Calidi Biotherapeutics, Lincoln Alternative Strategies, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, Biotherapeutics